NCT02135666

Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)

Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the long-term persistence of immunity to hepatitis A and B in adults who were vaccinated 16-20 years earlier with the combined hepatitis A and hepatitis B vaccine, Twinrix.

Conditions

• Hepatitis B
• Hepatitis A

Interventions

Type	Name	Description
PROCEDURE	Blood sampling	At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.

Timeline

• Start date: 2015-05-01
• Primary completion: 2019-10-01
• Completion: 2019-10-01
• First posted: 2014-05-12
• Last updated: 2015-11-18

Locations

1 site across 1 country: Czechia